These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2043 related articles for article (PubMed ID: 28052991)

  • 1. Myeloid-Derived Suppressor Cells.
    Gabrilovich DI
    Cancer Immunol Res; 2017 Jan; 5(1):3-8. PubMed ID: 28052991
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relevance of Interferon Regulatory Factor-8 Expression in Myeloid-Tumor Interactions.
    Abrams SI; Netherby CS; Twum DY; Messmer MN
    J Interferon Cytokine Res; 2016 Jul; 36(7):442-53. PubMed ID: 27379866
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasticity of myeloid-derived suppressor cells in cancer.
    Tcyganov E; Mastio J; Chen E; Gabrilovich DI
    Curr Opin Immunol; 2018 Apr; 51():76-82. PubMed ID: 29547768
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The New Era of Cancer Immunotherapy: Targeting Myeloid-Derived Suppressor Cells to Overcome Immune Evasion.
    De Cicco P; Ercolano G; Ianaro A
    Front Immunol; 2020; 11():1680. PubMed ID: 32849585
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Granulocytic Myeloid-Derived Suppressor Cells as Negative Regulators of Anticancer Immunity.
    Kramer ED; Abrams SI
    Front Immunol; 2020; 11():1963. PubMed ID: 32983128
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatic carcinoma-associated fibroblasts enhance immune suppression by facilitating the generation of myeloid-derived suppressor cells.
    Deng Y; Cheng J; Fu B; Liu W; Chen G; Zhang Q; Yang Y
    Oncogene; 2017 Feb; 36(8):1090-1101. PubMed ID: 27593937
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Suppressive role of myeloid-derived suppressor cells (MDSCs) in the microenvironment of breast cancer and targeted immunotherapies.
    Shou D; Wen L; Song Z; Yin J; Sun Q; Gong W
    Oncotarget; 2016 Sep; 7(39):64505-64511. PubMed ID: 27542274
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Myeloid-Derived Suppressor Cells: Immune-Suppressive Cells That Impair Antitumor Immunity and Are Sculpted by Their Environment.
    Ostrand-Rosenberg S; Fenselau C
    J Immunol; 2018 Jan; 200(2):422-431. PubMed ID: 29311384
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective Targeting of Myeloid-Derived Suppressor Cells in Cancer Patients Using DS-8273a, an Agonistic TRAIL-R2 Antibody.
    Dominguez GA; Condamine T; Mony S; Hashimoto A; Wang F; Liu Q; Forero A; Bendell J; Witt R; Hockstein N; Kumar P; Gabrilovich DI
    Clin Cancer Res; 2017 Jun; 23(12):2942-2950. PubMed ID: 27965309
    [No Abstract]   [Full Text] [Related]  

  • 10. Expansion and functions of myeloid-derived suppressor cells in the tumor microenvironment.
    Qu P; Wang LZ; Lin PC
    Cancer Lett; 2016 Sep; 380(1):253-6. PubMed ID: 26519756
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epithelial-mesenchymal transition: When tumor cells meet myeloid-derived suppressor cells.
    Cai J; Cui Y; Yang J; Wang S
    Biochim Biophys Acta Rev Cancer; 2021 Aug; 1876(1):188564. PubMed ID: 33974950
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Myeloid-derived suppressor cells and tumor escape from immune surveillance.
    Umansky V; Blattner C; Fleming V; Hu X; Gebhardt C; Altevogt P; Utikal J
    Semin Immunopathol; 2017 Apr; 39(3):295-305. PubMed ID: 27787613
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards.
    Bronte V; Brandau S; Chen SH; Colombo MP; Frey AB; Greten TF; Mandruzzato S; Murray PJ; Ochoa A; Ostrand-Rosenberg S; Rodriguez PC; Sica A; Umansky V; Vonderheide RH; Gabrilovich DI
    Nat Commun; 2016 Jul; 7():12150. PubMed ID: 27381735
    [TBL] [Abstract][Full Text] [Related]  

  • 14. mTOR masters monocytic myeloid-derived suppressor cells in mice with allografts or tumors.
    Wu T; Zhao Y; Wang H; Li Y; Shao L; Wang R; Lu J; Yang Z; Wang J; Zhao Y
    Sci Rep; 2016 Feb; 6():20250. PubMed ID: 26833095
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Secretory IgM Exacerbates Tumor Progression by Inducing Accumulations of MDSCs in Mice.
    Tang CH; Chang S; Hashimoto A; Chen YJ; Kang CW; Mato AR; Del Valle JR; Gabrilovich DI; Hu CC
    Cancer Immunol Res; 2018 Jun; 6(6):696-710. PubMed ID: 29650518
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Implications of MDSCs-targeting in lung cancer chemo-immunotherapeutics.
    Adah D; Hussain M; Qin L; Qin L; Zhang J; Chen X
    Pharmacol Res; 2016 Aug; 110():25-34. PubMed ID: 27157248
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Signal transducer and activator of transcription proteins: regulators of myeloid-derived suppressor cell-mediated immunosuppression in cancer.
    Ko HJ; Kim YJ
    Arch Pharm Res; 2016 Nov; 39(11):1597-1608. PubMed ID: 27572156
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Myeloid-derived suppressor cells and their role in pancreatic cancer.
    Pergamo M; Miller G
    Cancer Gene Ther; 2017 Mar; 24(3):100-105. PubMed ID: 27910857
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Myeloid-derived suppressor cells can be efficiently generated from human hematopoietic progenitors and peripheral blood monocytes.
    Casacuberta-Serra S; Parés M; Golbano A; Coves E; Espejo C; Barquinero J
    Immunol Cell Biol; 2017 Jul; 95(6):538-548. PubMed ID: 28108746
    [TBL] [Abstract][Full Text] [Related]  

  • 20. On the origin of myeloid-derived suppressor cells.
    Millrud CR; Bergenfelz C; Leandersson K
    Oncotarget; 2017 Jan; 8(2):3649-3665. PubMed ID: 27690299
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 103.